Genetic Profiling Reveals the Distinctions Among MTX‐Associated DLBCL, EBV‐Positive Mucocutaneous Ulcer, and EBV + DLBCL
Cancer Science · 2025-08 · 116 (8) · 2306-2316
DOI: 10.1111/cas.70111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 03.06.2025. Verfasst von Takumi Takahashi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Methotrexate, Ulcer. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, 50th Anniversary Research Grant, Kamoda grant.
Abstract (Originalsprache)
The WHO recently changed the outline of immunodeficiency/dysregulation (IDD)‐associated lymphoproliferative disorders (LPDs)/lymphomas from underlying IDD settings to an overarching framework and accommodates commonalities in histology, the involvement of various oncogenic viruses, and specific clinical/therapeutic consequences. A mutational analysis has been performed on post‐transplantation and HIV‐positive lymphomas, but not on other iatrogenic immunodeficiency (OII)‐associated LPDs mainly caused by methotrexate (MTX) to treat rheumatoid arthritis. We herein conducted next‐generation sequencing (NGS) to examine the genetic spectrum along with a fluorescence in situ hybridization analysis of 9p24.1 and PD‐L1 expression in 37 MTX‐associated diffuse large B‐cell lymphoma (DLBCL) cases, 17 Epstein–Barr virus (EBV)‐positive mucocutaneous ulcer (EBVMCU) cases, and 26 EBV‐positive DLBCL (EBV + DLBCL) cases. Targeted NGS identified 177 mutations. The mutation frequency was significantly higher in EBV − MTX‐DLBCL than in EBV‐positive LPDs/lymphomas (EBVMCU, EBV + MTX‐DLBCL, and EBV + DLBCL). Regrowth or resistance to spontaneous regression after MTX withdrawal was more likely in EBV − MTX‐DLBCL than in EBV + MTX‐DLBCL. Therefore, accumulated gene mutations, sustained by the restored immune status in EBV − MTX‐DLBCL, may affect clinical outcomes after MTX discontinuation. Several unique genetic findings were obtained for each category. Fewer TET2/DNMT3A and CD58 mutations in OII‐LPD/lymphomas (EBVMCU and MTX‐DLBCL) than in EBV + DLBCL indicate that clonal hematopoiesis and an immune evasion‐related background contributed less to lymphomagenesis in OII‐LPDs. MYD88 L265P / CD79B Y196 mutations were only detected in EBV − MTX‐DLBCL. SOCS1 mutations were significantly more frequent in EBV‐positive LPD/lymphoma categories, irrespective of the immune status, than in EBV − MTX‐DLBCL. These results reveal distinct genetic features among MTX‐DLBCL (EBV+/−), EBVMCU, and EBV + DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Department of Diagnostic Pathology, Saitama Red Cross Hospital, Saitama, Japan.
- Department of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan.
- Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
ORCID-Profile: Shuji Momose
Förderung
- Japan Society for the Promotion of Science
- 50th Anniversary Research Grant
- Kamoda grant
Zitieren
APA
Takahashi, T., Sawada, K., Yamashita, T., Yamamoto, W., Iijima, Y., Adachi, A., Kashimura, M., Tabayashi, T., Kizaki, M., Kaneko, T., Tamaru, J. I., Higashi, M., & Momose, S. (2025). Genetic Profiling Reveals the Distinctions Among MTX‐Associated DLBCL, EBV‐Positive Mucocutaneous Ulcer, and EBV + DLBCL. Cancer Science, 116(8), 2306-2316. https://doi.org/10.1111/cas.70111
Vancouver
Takahashi T, Sawada K, Yamashita T, Yamamoto W, Iijima Y, Adachi A, et al. Genetic Profiling Reveals the Distinctions Among MTX‐Associated DLBCL, EBV‐Positive Mucocutaneous Ulcer, and EBV + DLBCL. Cancer Science. 2025;116(8):2306-2316. doi:10.1111/cas.70111
BibTeX
@article{Takahashi2025,
author = {Takahashi, Takumi and Sawada, Keisuke and Yamashita, Takahisa and Yamamoto, Wataru and Iijima, Yosuke and Adachi, Akiko and Kashimura, Makoto and Tabayashi, Takayuki and Kizaki, Masahiro and Kaneko, Takahiro and Tamaru, Jun-Ichi and Higashi, Morihiro and Momose, Shuji},
title = {Genetic Profiling Reveals the Distinctions Among MTX‐Associated DLBCL, EBV‐Positive Mucocutaneous Ulcer, and EBV + DLBCL},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {8},
pages = {2306--2316},
doi = {10.1111/cas.70111}
}
EUVIMED